(Q38845891)

6 September 2017

1 reference

title

Drug-induced hepatotoxicity in cancer patients - implication for treatment (English)

1 reference

6 September 2017

1 reference

8

1 reference

6 September 2017

6

Daniele Santini

1 reference

6 September 2017

2

Grazia Armento

1 reference

6 September 2017

1

Bruno Vincenzi

1 reference

6 September 2017

Mariella Spalato Ceruso

series ordinal

3

object named as

Mariella Spalato Ceruso

1 reference

6 September 2017

Giovanna Catania

4

1 reference

6 September 2017

Mark Leakos

series ordinal

5

1 reference

6 September 2017

Giorgio Minotti

series ordinal

7

1 reference

6 September 2017

language of work or name

English

0 references

publication date

27 May 2016

1 reference

Expert Opinion on Drug Safety

6 September 2017

1 reference

6 September 2017

15

1 reference

6 September 2017

9

1 reference

6 September 2017

1219-1238

1 reference

Mechanisms of drug-induced liver injury

6 September 2017

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

Patterns of chemotherapy-induced hepatic injury and their implications for patients undergoing liver resection for colorectal liver metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

Drug-induced liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

Hepatotoxicity of chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

Hyperammonemia encephalopathy: an important cause of neurological deterioration following chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

Acute fatty liver of pregnancy and the microvesicular fat diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

Effects of oral 5-fluorouracil drugs on hepatic fat content in patients with colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

Reversible hepatic steatosis in patients treated with interferon alfa-2a and 5-fluorouracil

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

Demonstration of hepatic steatosis by computerized tomography in patients receiving 5-fluorouracil-based therapy for advanced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

The irinotecan/5-fluorouracil combination induces apoptosis and enhances manganese superoxide dismutase activity in HT-29 human colon carcinoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

Drug-induced liver injury through mitochondrial dysfunction: mechanisms and detection during preclinical safety studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

Chemotherapy, liver injury, and postoperative complications in colorectal liver metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

21 January 2018

Capecitabine: a review

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

Hepatic steatosis secondary to capecitabine: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

A fatal case of cholestatic liver failure probably related to gemcitabine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

Fatal cholestatic liver failure associated with gemcitabine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: Cancer and Leukemia Group B 9565.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

Phase II trial of pemetrexed disodium (ALIMTA, LY231514) in chemotherapy-naïve patients with advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

Front-line treatment of advanced non-small-cell lung cancer with MTA (LY231514, pemetrexed disodium, ALIMTA) and cisplatin: a multicenter phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

ALIMTA (pemetrexed disodium) as second-line treatment of non-small-cell lung cancer: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

Efficacy and safety of two doses of pemetrexed supplemented with folic acid and vitamin B12 in previously treated patients with non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

A phase I study of prolonged ambulatory infusion of Ifosfamide with oral mesna

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

Veno-occlusive liver disease after dacarbazine therapy (DTIC) for melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

The effects of impaired liver function on the elimination of antineoplastic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

Sinusoidal obstruction syndrome and nodular regenerative hyperplasia are frequent oxaliplatin-associated liver lesions and partially prevented by bevacizumab in patients with hepatic colorectal metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

Management of chemotherapy-associated hepatotoxicity in colorectal liver metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

Small-molecule anticancer compounds selectively target the hemopexin domain of matrix metalloproteinase-9

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

The resurgence of platinum-based cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

Molecular and biochemical investigations on the effect of quercetin on oxidative stress induced by cisplatin in rat kidney

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

High-dose carboplatin, cyclophosphamide, and BCNU with autologous bone marrow support: excessive hepatic toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

An evaluation of hepatotoxicity in breast cancer patients receiving injection Doxorubicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

Adriamycin chemotherapy--efficacy, safety, and pharmacologic basis of an intermittent single high-dosage schedule.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

A clinical review of bleomycin--a new antineoplastic agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

Trabectedin : a review of its use in the management of soft tissue sarcoma and ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

Development of Yondelis (trabectedin, ET-743). A semisynthetic process solves the supply problem.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

A review of trabectedin (ET-743): a unique mechanism of action.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

Trabectedin, a drug acting on both cancer cells and the tumour microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

Mode of action of trabectedin in myxoid liposarcomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

Trabectedin is a feasible treatment for soft tissue sarcoma patients regardless of patient age: a retrospective pooled analysis of five phase II trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

Trabectedin in soft tissue sarcomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

Steroid premedication markedly reduces liver and bone marrow toxicity of trabectedin in advanced sarcoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

Phase I and pharmacokinetic trial of paclitaxel in patients with hepatic dysfunction: Cancer and Leukemia Group B 9264.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

Activity of eribulin mesylate in heavily pretreated breast cancer granted access via the Cancer Drugs Fund

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

Specific genetic polymorphisms of IL10-592 AA and IL10-819 TT genotypes lead to the key role for inducing docetaxel-induced liver injury in breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

Population pharmacokinetic model for docetaxel in patients with varying degrees of liver function: incorporating cytochrome P4503A activity measurements

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

Safety and Efficacy of nab-Paclitaxel in the Treatment of Patients with Breast Cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

Pharmacokinetics and pharmacodynamics of nab-paclitaxel in patients with solid tumors: disposition kinetics and pharmacology distinct from solvent-based paclitaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

Abraxane, a novel Cremophor-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

Eribulin in pretreated metastatic breast cancer patients: results of the TROTTER trial-a multicenter retrospective study of eribulin in real life

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

Eribulin mesylate in pretreated breast cancer patients: a multicenter retrospective observational study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

Pharmacokinetics of eribulin mesylate in patients with solid tumors and hepatic impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

Recent advances in the development of dual topoisomerase I and II inhibitors as anticancer drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

Irinotecan pharmacogenomics

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

Design and validation of a histological scoring system for nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

Human mitochondrial topoisomerase I

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

Mitochondrial DNA topoisomerase I from human platelets

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

Immunological identification of human platelet mitochondrial DNA topoisomerase I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

Dosage adjustment and pharmacokinetic profile of irinotecan in cancer patients with hepatic dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

Topotecan in the management of cervical cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

A phase I and pharmacokinetic study of irinotecan in patients with hepatic or renal dysfunction or with prior pelvic radiation: CALGB 9863.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

Sensitivity to topoisomerase I inhibitors and cisplatin is associated with epidermal growth factor receptor expression in human cervical squamous carcinoma ME180 sublines

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

Hypoxia inducible factor-1: a novel target for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

A phase II study of gemcitabine plus oral etoposide in the treatment of patients with advanced nonsmall cell lung carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

A systematic review of FOLFOXIRI chemotherapy for the first-line treatment of metastatic colorectal cancer: improved efficacy at the cost of increased toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

Bevacizumab: in first-line treatment of advanced and/or metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

Hepatotoxicity induced by trastuzumab used for breast cancer adjuvant therapy: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

Trastuzumab emtansine for HER2-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

Phase IIa trial of trastuzumab emtansine with pertuzumab for patients with human epidermal growth factor receptor 2-positive, locally advanced, or metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

Phase I and pharmacokinetic study of trastuzumab emtansine in Japanese patients with HER2-positive metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

Part II: Liver function in oncology: towards safer chemotherapy use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

Erlotinib in previously treated non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure-safety relationship in patients with non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

Efficacy and safety of erlotinib monotherapy for Japanese patients with advanced non-small cell lung cancer: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

Mechanism-based inactivation of cytochrome P450 3A4 by lapatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

Lapatinib: a tyrosine kinase inhibitor with a clinical role in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

Fatal case of sorafenib-associated idiosyncratic hepatotoxicity in the adjuvant treatment of a patient with renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

Phase I study of pazopanib in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

Sunitinib-induced hyperammonemic encephalopathy in gastrointestinal stromal tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

Part I: Liver function in oncology: biochemistry and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

Imatinib mesylate-induced acute liver failure in a patient with gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

Nilotinib in a patient with postnecrotic liver cirrhosis related to imatinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

Imatinib mesylate-induced acute hepatitis in a patient treated for gastrointestinal stromal tumour

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

Practical management of tyrosine kinase inhibitor-associated side effects in GIST.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

Incidence and relative risk of hepatic toxicity in patients treated with anti-angiogenic tyrosine kinase inhibitors for malignancy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

Hepatotoxicity of tyrosine kinase inhibitors: clinical and regulatory perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

Genetic characterization to improve interpretation and clinical management of hepatotoxicity caused by tyrosine kinase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

Nivolumab plus ipilimumab in advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

Molecular mechanisms of T-cell tolerance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

Toxicities of Immunotherapy for the Practitioner

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

Incidence and risk factors for non-alcoholic steatohepatitis: prospective study of 5408 women enrolled in Italian tamoxifen chemoprevention trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

The association of nonalcoholic steatohepatitis and tamoxifen in patients with breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

Tamoxifen induced-non-alcoholic steatohepatitis (NASH): has the time come for the oncologist to be diabetologist

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

Mitochondrial injury in steatohepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

Serum leptin levels are associated with tamoxifen-induced hepatic steatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

Extended preoperative chemotherapy does not improve pathologic response and increases postoperative liver insufficiency after hepatic resection for colorectal liver metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

Abiraterone and increased survival in metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

Pharmacokinetics of intravenous 2-mercaptopropionylglycine in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

Increased elimination of paclitaxel by magnesium isoglycyrrhizinate in epithelial ovarian cancer patients treated with paclitaxel plus cisplatin: a pilot clinical study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

S-adenosylmethionine: jack of all trades and master of everything?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

Hepatoprotective effects of S-adenosyl-L-methionine against alcohol- and cytochrome P450 2E1-induced liver injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

Role of S-adenosyl-L-methionine in liver health and injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

Changes in S-adenosylmethionine synthetase in human liver cancer: molecular characterization and significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

S-adenosylmethionine (SAMe) therapy in liver disease: a review of current evidence and clinical utility

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

Bevacizumab protects against sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant XELOX/FOLFOX therapy of colorectal cancer liver metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

Identification of molecular pathways involved in oxaliplatin-associated sinusoidal dilatation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

Role of Macrophage Targeting in the Antitumor Activity of Trabectedin

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

Pseudocapillarization and associated energy limitation in the aged rat liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

A retrospective pooled analysis of trabectedin safety in 1,132 patients with solid tumors treated in phase II clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

Non-genetic risk factors and predicting efficacy for docetaxel-drug-induced liver injury among metastatic breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1194824

10.1080/14740338.2016.1194824

21 January 2018

Identifiers

DOI

1 reference

6 September 2017

1 reference